FDA Says User Fee Proposal Could Shorten Total Pre-market Review Times
This article was originally published in The Gray Sheet
Executive Summary
FDA's first crack at an industry user fee reauthorization proposal did not change review goals for 510(k)s, but did suggest some new processes to shorten overall review times for 510(k)s and PMAs alike.
You may also be interested in...
FDA Rejects Device Industry's Two-Year User Fee Plan
FDA says industry's reluctance to put a five-year user fee reauthorization plan on the table for discussion is delaying progress toward 2012 user fee legislation.
FDA Rejects Device Industry's Two-Year User Fee Plan
FDA says industry's reluctance to put a five-year user fee reauthorization plan on the table for discussion is delaying progress toward 2012 user fee legislation.
User Fee Negotiators Far Apart: Industry Seeks To Delay New Fee Levels Until FDA Improves Performance
Device industry reps say industry-paid FDA user fees should be reauthorized for only two years, not five, to allow ongoing changes to FDA's pre-market review programs to sink in before a more meaningful user fee package is passed.